eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Metabolic Diseases

I-Cell Disease (Mucolipidosis Type II): Treatment & Medication

Author: Karl S Roth, MD, Professor and Chair, Department of Pediatrics, Creighton University School of Medicine
Coauthor(s): William B Rizzo, MD, Professor, Department of Pediatrics, University of Nebraska Medical Center; Margaret M McGovern, MD, PhD, Professor and Chair of Pediatrics, Stony Brook University, New York
Contributor Information and Disclosures

Updated: Sep 1, 2009

Treatment

Medical Care

  • Available treatment for I-cell disease remains limited.
  • Bone marrow transplantation has been attempted in a small number of patients.

    • Data are limited; however, lysosomal enzyme levels seemed to normalize after transplant in at least one case.5
    • Although progression of the disease should theoretically cease, preexisting damage is usually irreversible.
    • Seriously consider the risks and benefits of bone marrow transplantation in the medical decision-making process.
  • Efforts can be made to maximize overall health maintenance.

    • Because these children have progressive failure to thrive, nutritional supplementation may be beneficial.
    • Promptly treat recurrent respiratory infections with antibiotics.

Consultations

  • Geneticist

    • For initial evaluation and diagnosis
    • To provide genetic counseling for recurrence risks
    • To provide prenatal testing for future offspring
  • Neurologist/developmental specialist

    • For initial evaluation of developmental delay
    • To recommend physical interventional services, such as physical therapy, occupational therapy, and speech therapy
  • Cardiologist: Baseline and serial evaluations are recommended because patients with I-cell disease eventually develop valvular disease and signs of poor cardiac function.

Diet

  • Because these children have progressive failure to thrive, nutritional supplementation may be beneficial.

Medication

Drug therapy is not currently a component of the standard of care in lysosomal storage disorder. See Treatment.

More on I-Cell Disease (Mucolipidosis Type II)

Overview: I-Cell Disease (Mucolipidosis Type II)
Differential Diagnoses & Workup: I-Cell Disease (Mucolipidosis Type II)
Treatment & Medication: I-Cell Disease (Mucolipidosis Type II)
Follow-up: I-Cell Disease (Mucolipidosis Type II)
Multimedia: I-Cell Disease (Mucolipidosis Type II)
References
[ CLOSE WINDOW ]

References

  1. Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta. Apr 2009;1793(4):710-25. [Medline].

  2. Leroy JG, DeMars RI, Opitz JM. I-cell disease. Birth Defects Orig Artic Ser. 1969;4:174-85.

  3. Spranger JW, Wiedemann HR. The genetic mucolipidoses. Diagnosis and differential diagnosis. Humangenetik. 1970;9(2):113-39. [Medline].

  4. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. Jul-Aug 1999;105(1-2):151-6. [Medline].

  5. Krivan G, Timar L, Goda V, et al. Bone marrow transplantation in non-malignant disorders. Bone Marrow Transplant. Dec 1998;22 Suppl 4:S80-3. [Medline].

  6. Bocca G, Monnens LA. Defective proximal tubular function in a patient with I-cell disease. Pediatr Nephrol. Aug 2003;18(8):830-2. [Medline].

  7. Breningstall GN, Tubman DE. Magnetic resonance imaging in a patient with I-cell disease. Clin Neurol Neurosurg. May 1994;96(2):161-3. [Medline].

  8. Goodman ML, Pang D. Spinal cord injury in I-cell disease. Pediatr Neurosci. 1988;14(6):315-8. [Medline].

  9. Gopaul KP, Crook MA. The inborn errors of sialic acid metabolism and their laboratory investigation. Clin Lab. 2006;52(3-4):155-69. [Medline].

  10. Kawashima I, Ohsawa M, Fukushige et al. Cytochemical analysis of storage materials in cultured skin fibroblasts from patients with I-cell disease. Clin Chim Acta. Mar 2007;378(1-2):142-6. [Medline].

  11. Kornfeld S, Sly WS. I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. Metab Mol Bases Inherited Dis. 2001;3:3469-82.

  12. Kudo M, Brem MS, Canfield WM. Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta -subunits precursor gene. Am J Hum Genet. Mar 2006;78(3):451-63. [Medline].

  13. Leroy JG, Martin JJ. Mucolipidosis II (I-cell disease): present status of knowledge. Birth Defects Orig Artic Ser. 1975;DA - 19760301(6):283-93. [Medline].

  14. Leroy JG, Spranger JW, Feingold M, Opitz JM, Crocker AC. I-cell disease: a clinical picture. J Pediatr. Sep 1971;79(3):360-5. [Medline].

  15. Tiede S, Storch S, Lubke T, et al. Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat Med. Oct 2005;11(10):1109-12. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

I-cell disease, mucolipidosis type II, mucolipidosis II, ML2, ML II, N -acetylglucosaminyl-1-phosphotransferase deficiency, GNPTA deficiency, inclusion cell disease, I-cell disease, I cell disease, lysosomal storage disorder, Hurler syndrome, mucopolysaccharidoses 1H, MPS 1H, mucopolysacchariduria, phase-dense intracytoplasmic inclusions, sphingolipidoses

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Karl S Roth, MD, Professor and Chair, Department of Pediatrics, Creighton University School of Medicine
Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Clinical Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, Society for Pediatric Research, and Southern Society for Pediatric Research
Disclosure: MDS Pharma Salary Employment

Coauthor(s)

William B Rizzo, MD, Professor, Department of Pediatrics, University of Nebraska Medical Center
William B Rizzo, MD is a member of the following medical societies: American Society of Human Genetics and Society for Inherited Metabolic Disorders
Disclosure: Nothing to disclose.

Margaret M McGovern, MD, PhD, Professor and Chair of Pediatrics, Stony Brook University, New York
Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics and American Society of Human Genetics
Disclosure: Genzyme Grant/research funds PI

Medical Editor

Edward Kaye, MD, Vice President of Clinical Research, Genzyme Corporation
Edward Kaye, MD is a member of the following medical societies: American Academy of Neurology, American Society of Gene Therapy, American Society of Human Genetics, Child Neurology Society, and Society for Inherited Metabolic Disorders
Disclosure: Genzyme Corporation Salary Management position

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Margaret M McGovern, MD, PhD, Professor and Chair of Pediatrics, Stony Brook University, New York
Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics and American Society of Human Genetics
Disclosure: Genzyme Grant/research funds PI

CME Editor

Paul D Petry, DO, FACOP, FAAP, Consulting Staff, Freeman Pediatric Care, Freeman Health System
Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Chief Editor

Bruce Buehler, MD, Professor, Department of Pediatrics, Pathology and Microbiology, Executive Director, Hattie B Munroe Center for Human Genetics, University of Nebraska Medical Center
Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.